This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | MicrobiomeTrials
← Back to trials NCT04931342
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2021-10-07Est. Completion: 2028-02-28
Enrollment target: 176 participantsLocations UCSF Helen Diller Family CCC, San Francisco, California, United States Washington University School of Medicine, St Louis, Missouri, United States Levine Cancer Institute, Charlotte, North Carolina, United States Ohio State University, Columbus, Ohio, United States University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States Texas Oncology - Gulf Coast, The Woodlands, Texas, United States Virginia Oncology Associates, Norfolk, Virginia, United States University of Washington - Seattle Cancer Care Alliance, Seattle, Washington, United States Cabrini Hospital, Malvern, Victoria, Australia Princess Margaret Cancer Center, Toronto, Ontario, Canada McGill University Health Centre - Glen Site, Montreal, Quebec, Canada Gynekologicko-porodnicka klinika, Prague, Czechia CHU Besançon - Hôpital Jean Minjoz, Besançon, France Centre Francois Baclesse, Caen, France Centre Leon Berard, Lyon, France Groupe Hospitalier Diaconesses, Paris, France Other microbiome trials you might be interested in Hormone Receptor-Positive Breast Cancer HER2 Low Breast Carcinoma Early-Stage Breast Cancer
This is a single-center, open-label, randomized phase II clinical trial designed to evaluate the efficacy and safety of …
Guangzhou, China Est. completion Sep 15, 2028
Ovarian Cancer
This is a single site, open label, Phase 1 study using a 3 + 3 dose escalation design in two cohorts of adults with recu…
Palo Alto, United States Est. completion Jan 2027
Centre Eugène Marquis, Rennes, France
ICO - Site René Gauducheau, Saint-Herblain, France
Institut Claudius Regaud, Toulouse, France
Gustave Roussy, Villejuif, France
Kliniken Essen-Mitte Evang. Huyssens-Stiftung, Klinik für Gynäkologie und gynäkologische Onkologie, Essen, Germany
Universitätsklinikum Mannheim, Mannheim, Germany
A.O. U. Consorziale Policlinico di Bari, Bari, Apulia, Italy
Istituto Tumori Napoli, Naples, Campania, Italy
Policlinico Universitario Agostino Gemelli, Rome, Lazio, Italy
IRCCS S. Raffaele, Milan, Lombardy, Italy
LLC Medscan, Moskva, Moscow Oblast, Russia
Samsung Medical Center, Seoul, South Korea
Seoul National University Hospital, Seoul, South Korea
Severance Hospital, Yonsei University Health System, Seoul, South Korea
Asan Medical Center, Seoul, South Korea
Institutio Catalan De Oncologia, Barcelona, Spain
Hospital Universitario 12 de Octubre, Madrid, Spain
Hospital Universitario La Paz, Madrid, Spain
Hospital Clinico Universitario Virgen de la Victoria, Málaga, Spain
Hôpitaux Universitaires de Genève, Geneva, Switzerland
Adana Baskent University Medical Faculty; Oncology, Adana, Turkey (Türkiye)
Baskent Universitesi Ankara Hastanesi; Tıbbi Onkoloji Bölümü, Ankara, Turkey (Türkiye)
Koc University Medical Faculty; Department of Gynecology & Obstetrics, Istanbul, Turkey (Türkiye)
Western General Hospital, Edinburgh, United Kingdom
University College London Hospitals NHS Foundation Trust - University College Hospital, London, United Kingdom Ovarian Cancer Genetic Testing Genetic Counseling
The goal of this clinical trial is to assess patients' knowledge and attitudes about genetic testing before and after vi…
Lexington, United States Est. completion Jul 2027